Cover Image
市場調查報告書

Rho相關蛋白激酶2:開發中產品分析

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 410996
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
Rho相關蛋白激酶2:開發中產品分析 Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 58 Pages
簡介

本報告提供以Rho相關蛋白激酶2為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Rho相關蛋白激酶2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Anacor Pharmaceuticals Inc
  • Astex Pharmaceuticals Inc
  • BioAxone BioSciences Inc
  • HitGen LTD
  • Kadmon Corp LLC
  • Vertex Pharmaceuticals Inc
  • Vichem Chemie Research Ltd

藥物簡介

  • AN-3485
  • AT-13148
  • BA-1049
  • BA-1076
  • KD-025
  • KL-00148
  • Rho相關蛋白激酶2抑制劑
  • 心血管·眼科學·腫瘤學用ROCK-2抑制劑
  • 自體免疫疾病ROCK2選擇性抑制劑
  • TRN-101
  • TRX-101
  • VX-210

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1002TDB

Summary:

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The latest report Rho Associated Protein Kinase 2 - Pipeline Review, H2 2017, outlays comprehensive information on the Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 8 and 2 respectively. Report covers products from therapy areas Cardiovascular, Immunology, Ophthalmology, Central Nervous System, Musculoskeletal Disorders, Respiratory, Dermatology, Gastrointestinal, Metabolic Disorders and Oncology which include indications Glaucoma, Fibrosis, Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Acute Spinal Cord Injury, Alzheimer's Disease, Autoimmune Disorders, Cerebrovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), Contact Dermatitis, Huntington Disease, Hypersensitivity, Hypertension, Idiopathic Pulmonary Fibrosis, Inflammation, Inflammatory Bowel Disease, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Arterial Hypertension, Solid Tumor and Traumatic Spinal Cord Injury.

Furthermore, this report also reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
  • The report reviews Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Overview
    • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • Astex Pharmaceuticals Inc
    • BioAxone BioSciences Inc
    • HitGen LTD
    • Kadmon Corp LLC
    • Pfizer Inc
    • Redx Pharma Plc
    • Vertex Pharmaceuticals Inc
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Drug Profiles
    • AMA-0825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-3485 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-13148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BA-1049 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BA-1076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KL-00148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KL-01045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology, Metabolic Disorders and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VX-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Dormant Products
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Discontinued Products
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 11, 2017: Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017
      • Aug 02, 2017: BioAxone BioSciences Receives Notice of Award for NIH/SBIR Funding of IND-Enabling Studies to Continue Development of BA-1049 to Treat Cerebral Cavernous Malformations
      • Jul 25, 2017: Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
      • Jul 11, 2017: Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
      • Jun 23, 2017: Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease at R&D Day
      • May 11, 2017: Kadmon to Present Clinical and Preclinical Data Highlighting the Role of ROCK2 Signaling in Immune System Function at AAI Annual Meeting
      • May 11, 2017: BioAxone BioSciences Announces New Hires to Support Investigational New Drug Filing
      • May 02, 2017: BioAxone BioSciences Continues Plans for Growth with Manufacturing Contract
      • Apr 12, 2017: Kadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients
      • Mar 28, 2017: Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis
      • Sep 21, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
      • Sep 21, 2016: Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
      • Jul 19, 2016: Kadmon Data Published in Science Signaling Show ROCK2 Signaling as a Key Modulator of T Follicular Helper Cell Function in Autoimmune Diseases
      • Jun 03, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Idiopathic Pulmonary Fibrosis
      • Mar 21, 2016: Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Astex Pharmaceuticals Inc, H2 2017
  • Pipeline by BioAxone BioSciences Inc, H2 2017
  • Pipeline by HitGen LTD, H2 2017
  • Pipeline by Kadmon Corp LLC, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Redx Pharma Plc, H2 2017
  • Pipeline by Vertex Pharmaceuticals Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top